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i.org/1arteries with multidetector computed tomography (MDCT) in a propensity scoreematched
population of patients with a bicuspid versus a tricuspid aortic valve. From an ongoing
clinical registry of patients who underwent MDCT, 70 patients with bicuspid aortic valve
and 210 patients with tricuspid aortic valve were matched based on age, gender, cardio-
vascular risk factors, chest pain symptoms, and MDCT indication. Aortic valve calcium
and the presence and severity of coronary artery disease were analyzed. Patients were
divided into age quintiles. The median Agatston coronary artery score (27 [0 to 563] vs
0 [0 to 57], p [ 0.003) was higher in patients with a tricuspid aortic valve compared with
those with a bicuspid aortic valve. In contrast, patients with bicuspid aortic valve had a
signiﬁcantly larger calcium volume of the aortic valve than those with tricuspid aortic valve
(391 [43 to 2,028] mm3 vs 0 [0 to 1,844] mm3, p <0.001). In patients with bicuspid aortic
valve, the calciﬁcation process of the aortic valve started at an earlier age (second quintile
35 to 51 years) compared with those with tricuspid aortic valve, whereas the coronary
atherosclerosis process was similar in both groups. In conclusion, patients with bicuspid
aortic valve show larger aortic valve calcium load and at earlier age than those with
tricuspid aortic valve, independently from the extent of calcium in the coronary arteries.
Calciﬁc deposits were heavier in bicuspid than in tricuspid valves.  2016 Elsevier Inc.
All rights reserved. (Am J Cardiol 2016;118:1533e1538)Calciﬁc aortic valve stenosis has been associated with the
presence of coronary atherosclerosis. Both processes share
common pathophysiological mechanisms: increased me-
chanical stress and reduced shear stress result in endothelial
damage, which is the ﬁrst step of the inﬂammation, ﬁbrosis,
and calciﬁcation cascade.1,2 In the tricuspid aortic valve, the
increased mechanical stress is located near to the hinge
points of the aortic cusps anchoring into the aortic root wall,
whereas the noncoronary cusp shows the least shear stress
leading to the characteristic distribution of the valvularent of Cardiology, Leiden University Medical Center,
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pathophysiological differences between calciﬁc aortic ste-
nosis and the development of atherosclerosis. These differ-
ences may explain why statin therapy effectively halts the
atherosclerosis process and stabilizes the atherosclerotic
plaque of coronary arteries but does not affect the progres-
sion of calciﬁc aortic valve stenosis.4e6 Furthermore, in
bicuspid aortic valves, the mechanical and shear stress dis-
tribution is different from that of tricuspid valves, which
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1534 The American Journal of Cardiology (www.ajconline.org)develops at an earlier stage than in patients with tricuspid
aortic valve.1,2,7 However, the evidence correlating the
amount of calciﬁc deposits of the aortic valve in bicuspid
aortic valves and the development of coronary artery
atherosclerosis in relation to age is scarce. Multidetector row
computed tomography (MDCT) enables accurate quantiﬁ-
cation of aortic valve calcium8 and provides a high diag-
nostic accuracy for coronary artery disease (CAD).9 In
propensity scoreematched populations, the present study
compared the extent of aortic valve calcium and the pres-
ence of coronary atherosclerosis, as evaluated with MDCT,
in patients with bicuspid versus tricuspid aortic valve across
different ages.
Methods
From an ongoing clinical registry of patients who un-
derwent clinically indicated MDCT at the Leiden Uni-
versity Medical Center (Leiden, The Netherlands),9 85
patients with a bicuspid aortic valve were identiﬁed.
Additional 713 patients with a tricuspid aortic valve were
identiﬁed. A propensity score was used to match in a 1:3
fashion patients with a bicuspid aortic valve to patients
with a tricuspid aortic valve (see details in the “Statistical
Analysis” section). The resulting population comprised 70
patients with bicuspid aortic valve and 210 patients with
tricuspid aortic valve. MDCT data of aortic valve calcium
and the presence of coronary atherosclerosis were evalu-
ated and compared between patients with a bicuspid
versus a tricuspid aortic valve. The presence and severity
of aortic regurgitation and aortic stenosis were assessed
with transthoracic echocardiography according to current
recommendations.10,11 Data were prospectively collected
in the departmental electronic clinical ﬁles (EPD Vision,
version 11.3.26.0; Leiden, The Netherlands) and retro-
spectively analyzed. The institutional review board
approved this retrospective analysis of clinically acquired
data and waived the need of patient written informed
consent.
MDCT scans were acquired with a 64-slice MDCT
scanner (n ¼ 6; Aquilion 64; Toshiba Medical Systems,
Otawara, Japan) or with a volumetric 320-slice MDCT
scanner (n ¼ 274; AquilionOne; Toshiba Medical Sys-
tems, Tochigi-ken, Japan).9 For the 64-slice scanner, a
collimation of 64  0.5 mm, rotation time of 400 ms, and
tube voltages and currents (adjusted to the body mass in-
dex) of 120 to 135 kV and 250 to 500 mA were used and
for the 320-slice scanner a collimation of 320  0.5 mm,
rotation time of 350 ms, and tube voltages and currents of
100 to 135 kV and 200 to 580 mA. Unless contraindicated,
oral b blockers were administered to patients with heart
rates >65 beats/min after careful evaluation of the hemo-
dynamic conditions. The MDCT acquisition protocol
started with a prospective calcium scan (collimation
4  3.0 mm, tube voltage and current of 120 kV and
200 mA), followed by the contrast-enhanced MDCT cor-
onary angiography. Based on the patient’s body weight, 80
to 115 ml of ionic contrast medium (Ultravist 370; Bayer,
Whippany, New Jersey) was administered intravenously if
the 64-slice system was used (ﬂow rate of 5.0 ml/s) and 60
to 105 ml of contrast material was injected in 3 phases ifthe 320-slice system was used: ﬁrst 60 to 80 ml of contrast
material (ﬂow rate 5.0 to 6.0 ml/s), followed by a 1:1
mixture of contrast and saline and additional 25 ml of
saline (ﬂow rate 3.0 ml/s). Triggering of the scan was
synchronized with arrival of the contrast material in the
left ventricle using automated peak enhancement detection
(threshold of þ180 Hounsﬁeld units). For the 64-slice
system, the electrocardiogram was simultaneously recor-
ded during image acquisition for retrospective gating and
image reconstruction. With the 320-slice scanner, the
electrocardiogram was simultaneously registered for pro-
spective triggering of the data. Phase windows were set at
70% to 80% or 30% to 80% of the RR interval in patients
with regular heart rates of 65 or >65 beats/min, whereas
target scans at 75% or 45% of the RR interval were per-
formed for irregular heart rates of 65 or >65 beats/min.
When the entire cardiac cycle was scanned (i.e., patients
who underwent transcatheter aortic valve implantation),
dose modulation was applied with the maximal tube cur-
rents at 75%, 65% to 85%, or 30% to 80% of the RR in-
terval in patients whose heart rates were <60, 60 to 65, or
>65 beats/min, respectively.9 MDCT data were recon-
structed initially at 75% of the RR interval with a slice
thickness and reconstruction interval of 0.5 and 0.25 mm.
In the presence of multiple phases, additional phases with
the least motion artifacts were reconstructed. Subse-
quently, for off-line image analysis, the reconstructed data
sets were transferred to an external workstation (Vitrea 2;
Vital Images, Plymouth, Minnesota).
The noncontrast calcium scans were used to assess the
Agatston coronary artery calcium score and the calcium
score and calcium volume of the aortic valve (including a
volume from the aortic annulus until the level of the coro-
nary ostia).8,12 To accurately exclude contiguous calcium
located in the coronary arteries and mitral valve annulus
from the calcium analysis of the aortic valve, the aortic
valve calcium was also evaluated on the higher spatial,
contrast-enhanced images enabling an accurate delineation
of the calcium by multiplanar reformation planes. On the
contrast-enhanced images, the presence of signiﬁcant CAD
was deﬁned as 50% stenosis.9 The location of the aortic
valve calcium was also assessed on the contrast-enhanced
MDCT images.13
Continuous data are presented as mean  SD or as
median and interquartile range (or with the minimal and
maximal values), as appropriate. Categorical data are dis-
played as frequencies and percentages. To control the ef-
fects of confounding factors, propensity score matching
was performed using a multivariate binary logistic regres-
sion model with the type of aortic valve (bicuspid or
tricuspid) as dependent variable. Cardiovascular risk fac-
tors (age, gender, hypertension, hypercholesterolemia,
diabetes, and smoking), the presence of chest pain symp-
toms and the MDCT clinical indication were added as
covariates. The Hosmer-Lemeshow goodness-of-ﬁt test
was used to check the accuracy of the model. Subsequently,
propensity score 1:3 (bicuspid:tricuspid) matching was
performed with replacement and a caliper of 0.22 that was
twice the SD of the probability.14 Differences between
patients with a bicuspid aortic valve and those with a
tricuspid aortic valve were analyzed using the unpaired
Table 1
Baseline characteristics
Variable Total Population
(n ¼ 798)
Propensity Score Matched
(n ¼ 280)
Bicuspid aortic valve
(n ¼ 85)
Tricuspid aortic valve
(n ¼ 713)
p-value Bicuspid aortic valve
(n ¼ 70)
Tricuspid aortic valve
(n ¼ 210)
p-value
Age (years) 51  17 56  16 0.006 52  17 55  21 0.298
Men 52 (61%) 388 (54%) 0.236 40 (57%) 129 (61%) 0.526
Chest pain symptoms 32 (38%) 264 (37%) 0.991 24 (34%) 80 (38%) 0.826
Hypertension 39 (46%) 268 (38%) 0.137 27 (39%) 87 (41%) 0.673
Hypercholesterolemia 20 (24%) 123 (17%) 0.154 15 (21%) 54 (26%) 0.471
Diabetes mellitus 6 (7%) 62 (9%) 0.609 6 (9%) 20 (10%) 0.812
Smoker 13 (15%) 93 (13%) 0.563 9 (13%) 30 (14%) 0.765
CT indication
Radiofrequency catheter ablation 14 (16%) 200 (28%) 0.023 14 (20%) 44 (21%) 0.865
Aortic valve replacement 29 (34%) 107 (15%) <0.001 16 (23%) 56 (27%) 0.528
Coronary artery disease 28 (33%) 375 (53%) 0.001 28 (40%) 85 (40%) 0.944
Coronary anomaly 14 (16%) 31 (4%) <0.001 12 (17%) 25 (12%) 0.262
Hypertension ¼ history of high blood pressure and/or on antihypertensive treatment; Hypercholesterolemia ¼ history of hypercholesterolemia deﬁned as a
serum total cholesterol of 230 mg/dl and/or serum triglycerides 200 mg/dl and/or on statin therapy.
Table 2
Clinical and echocardiographic characteristics
Variable Aortic valve structure p-value
Bicuspid
(n ¼ 70)
Tricuspid
(n ¼ 210)
Systolic blood pressure (mmHg) 130  20 133  22 0.457
Diastolic blood pressure (mmHg) 79  11 79  13 0.915
Glomerular ﬁltration rate (ml/min/1.73 m2) 88  24 91  27 0.371
Echocardiography
Left ventricular ejection fraction (%) 63  15 61  11 0.246
Moderate or severe aortic regurgitation 14 (20%) 10 (5%) <0.001
Moderate or severe aortic stenosis 29 (41%) 53 (28%) 0.035
Medication
b-blockers 26 (37%) 91 (43%) 0.363
Angiotensin-converting enzyme inhibitor 12 (17%) 42 (20%) 0.600
Calcium channel blocker 8 (11%) 22 (11%) 0.823
Diuretics 13 (19%) 50 (24%) 0.363
Statins 12 (17%) 65 (31%) 0.025
Aspirin 15 (21%) 52 (25%) 0.571
Oral anticoagulants 15 (21%) 51 (24%) 0.626
Table 3
Multi-detector row computed tomography data
Variable Aortic valve structure p-value
Bicuspid
(n ¼ 70)
Tricuspid
(n ¼ 210)
Coronary artery disease
Agatston calcium score 0 (0-57) 27 (0-563) 0.003
Signiﬁcant stenosis 50% 11 (16%) 51 (24%) 0.135
Aortic valve calcium
Calcium volume (mm3) (IQR) 391 (43-2028) 0 (0-1844) <0.001
Calcium volume (mm3) (min-max) 391 (0-8547) 0 (0-6952) <0.001
Agatston calcium score 510 (55-2637) 0 (0-2301) <0.001
Valvular Heart Disease/Aortic Valve and Coronary Calcium 1535Student t test or the Mann-Whitney U test, as appropriate,
for continuous data and with the chi-square test for cate-
gorical data. Statistical tests were 2 sided, and p values
<0.05 were considered signiﬁcant. All statistical analyses
were performed with the SPSS software (version 20.0;
SPSS Inc., Chicago, Illinois).Results
Table 1 summarizes the characteristics of patients with
bicuspid and those with tricuspid aortic valve before
(n ¼ 798) and after applying the propensity score matching
(n ¼ 280) (Hosmer-Lemeshow goodness-of-ﬁt test
p ¼ 0.67). After propensity score matching, there were no
differences in cardiovascular risk factors, chest pain symp-
toms, and in indication for MDCT between both groups(Table 1). Patients with a bicuspid aortic valve had more
frequently moderate and severe aortic regurgitation (20% vs
5%, p <0.001) and moderate and severe aortic stenosis
(41% vs 28%, p ¼ 0.035) compared with their counterparts
(Table 2).
MDCT data of the aortic valve calcium and coronary
atherosclerosis of the patient population are summarized in
Table 3. The median Agatston coronary artery score was
higher in patients with a tricuspid aortic valve compared
with those with a bicuspid aortic valve (27 [0 to 563] vs 0 [0
to 57], respectively; p ¼ 0.003; Table 3). In contrast, the
median Agatston score and calcium volume of the aortic
valve were higher in the patients with bicuspid aortic valve
compared with those with tricuspid aortic valve (510 [55 to
2,637] vs 0 [0 to 2,301] and 391 [43 to 2,028] mm3 vs 0 [0
to 1,844] mm3, respectively; p <0.001 for both; Table 3).
The frequency of multivessel disease did not differ signiﬁ-
cantly between patients with a bicuspid and a tricuspid
aortic valve (5.7% vs 11.9%, p ¼ 0.297). Compared with
patients with tricuspid aortic valves, those with bicuspid
aortic valve showed more frequently calciﬁc deposits of the
aortic valve (47 [67%] compared with 68 [32%], p <0.001).
The most frequent calciﬁed spot in patients with tricuspid
Figure 1. Presence of aortic valve and coronary artery calcium displayed per age quintile and per type of aortic valve. AOV ¼ aortic valve.
1536 The American Journal of Cardiology (www.ajconline.org)valves was the noncoronary cusp (90%), whereas in patients
with bicuspid aortic valves, the fusion raphe (60%) was the
most frequent location of calciﬁc deposits followed by the
cusp located in relation with the origin of the left main
coronary artery (59%).
The distribution of aortic valve calcium (calcium volume
>0 mm3) and Agatston coronary artery score >0 across the
age quintiles in patients with bicuspid versus tricuspid aortic
valve is graphically displayed in Figure 1. In patients with
bicuspid aortic valve, the calciﬁc deposits of the aortic valve
were observed at an earlier age (second quintile 35 to
51 years) compared with those with tricuspid aortic valve,
whereas the coronary atherosclerosis process was similar in
both groups.
Discussion
The complete pathogenesis of calciﬁc aortic valve pro-
cess has not been yet fully elucidated challenging the
development of an effective therapy to slow its onset and
progression. Frequently, calciﬁc aortic valve process and
coronary artery atherosclerosis are considered as having
similar pathophysiological underlying mechanisms and
both are associated with the aging process.1,15 In patients
with calciﬁc aortic valve stenosis, the prevalence of CAD is
high and it may be as prevalent as 75% of patients referred
for transcatheter aortic valve implantation.16,17 This high
prevalence may partly be explained by a common patho-
physiological cascade for both processes (aortic valve
calciﬁcation and coronary atherosclerosis) characterized by
initial mechanical stress causing endothelial damage that
enables inﬁltration of lipids and subsequently triggers
inﬂammation, ﬁbrosis, and calcium deposition.2 However,
despite these pathophysiological similarities, there are
fundamental differences between the development andprogression of calciﬁc aortic valve and coronary athero-
sclerosis. Quantiﬁcation of 18F-ﬂuorodeoxyglucose (FDG)
and 18F-sodium ﬂuoride (NaF) uptake using positron
emission tomography and computed tomography has
demonstrated that active calciﬁcation rather than inﬂam-
mation is the predominant pathophysiological process in
aortic valve calciﬁcation, whereas inﬂammation is the more
dominant process in regions of atherosclerosis.18e21 Dweck
et al20 assessed the calcium scores and the 18F-FDG and
18F-NaF tracer uptake of the aortic valve and of the cor-
onary arteries in 101 patients with calciﬁc aortic valve
disease. Despite that 90% of these patients had coexistent
calcium in the coronary arteries (coronary calcium score
>0), there was only a weak correlation between the cal-
cium scores of the aortic valve and the coronary arteries
(r2 ¼ 0.039, p ¼ 0.049). For calciﬁcation activity, the
maximal 18F-NaF uptake was higher in the aortic valve
than in the coronary arteries and the correlation between
valvular and coronary artery 18F-NaF uptake was
weak (r2 ¼ 0.174, p <0.001).20 In contrast, the 18F-FDG
uptake was lower in the aortic valve than in regions of
atherosclerosis.20
The present study provides further insights into the
pathophysiological differences between aortic valve calci-
ﬁcation and coronary atherosclerosis by studying the coro-
nary and aortic valve calciﬁcation burden in patients with a
bicuspid aortic valve. Bicuspid aortic valves tend to become
calciﬁed 2 decades earlier than tricuspid aortic valves and
this process may be independent of the coronary athero-
sclerotic process. The current data showed that in patients
with a bicuspid aortic valve, the onset and progression of
aortic valve calciﬁcation occurred earlier and independent
from coronary atherosclerosis, whereas in those with
tricuspid aortic valves, valvular calciﬁcation, and coronary
atherosclerosis increased along with increasing age. Aortic
Valvular Heart Disease/Aortic Valve and Coronary Calcium 1537valve calciﬁcation occurs more rapidly in bicuspid than in
tricuspid aortic valves,4,22 and it has been shown that
calciﬁc bicuspid aortic valve stenosis accounts for almost
50% of isolated aortic valve replacement.23 Currently, it is
not fully understood why the bicuspid aortic valve becomes
earlier calciﬁed than a tricuspid aortic valve.7 Histopatho-
logically, the calciﬁcation process of bicuspid aortic valves
appears to be similar to that of tricuspid aortic valves,24,25
and it is, therefore, assumed that especially the altered me-
chanical and shear stress contribute to the premature calci-
ﬁcation in bicuspid aortic valves.1,2,7,24 Compared with a
tricuspid aortic valve, mechanical forces are less efﬁciently
distributed in bicuspid aortic valves and the higher tensile
stress may provoke an earlier onset and a more rapid pro-
gression of valvular calciﬁcation.2,7,24 The results of the
present study also point out other factors beyond cardio-
vascular risk proﬁle that contribute to calciﬁc aortic valve
stenosis in patients with bicuspid aortic valve. Correlation of
blood ﬂow patterns and shear stress within bicuspid aortic
valves, as recently demonstrated by 4-dimensional cardiac
magnetic resonance imaging,26 with the distribution of
valvular calcium on MDCT may provide a better under-
standing of the pathophysiology of aortic valve calciﬁcation
in this subgroup of patients.
Some limitations should be acknowledged. The present
study was observational. Although longitudinal follow-up
with MDCT would not be feasible because of the associ-
ated radiation burden, echocardiographic follow-up in terms
of progression of hemodynamically signiﬁcant aortic valve
dysfunction would have been of interest. Furthermore,
propensity score matching is a practical statistical approach
that has enabled us to include a signiﬁcant number of pa-
tients. Inclusion of matched pairs would have strengthened
the results if the statistical approach would have led a
similar number of patients to that included in the present
study.
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